

Proventa International's 11th Annual

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING WEST COAST USA 2024

Assessing, Choosing And Optimizing The Right Set Of Data And Methodologies To Help With Finding Effective Modalities And Techniques For Drug Discovery Biology

BOOK NOW

NEW FOR 2024:

Strategic Partnerships, **Investment & Collaborations**

Featuring Industry Leaders and Decision Makers:



Adam Mullick Vice President, Cardiovascular **Drug Discovery** Ionis Pharma



Amish Patel Senior Vice President **Technical Operations** Calidi **Biotherapeutics**



Dimitra Chalkia Vice President. Computational Biology Athos Therapeutics



Geza Ambrus-Aikelin Executive Director, Biology Odyssey Therapeutics



Igor Nasonkin Co-founder & Phythera Therapeutics



lohn Leonard Chief Executive Officer Aeona **Pharmaceuticals**



Stephanie Truhlar Associate Vice President Eli Lilly











KEYNOTE PRESENTATIONS



PANEL DISCUSSION



LOCATION



What Makes **Our Strategy** Meetings So Unique?

Proud to Partners with:



















Proventa International's Strategy Meetings are a completely unique experience.

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING WEST COAST USA 2024

Tuesday, 21st May 2024 & Hard Rock Hotel San Diego

We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.



To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.



By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.



roups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.



The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings



PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.



STRATEGIC NETWORKING


Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that

Seniority of Attendees

- **Director Level**
- President / VP
- **Department Head**
- Other
- Team Lead
- C-Level
- Scientist
- Academia
- Manager

BOOK NOW!

Biology Specialist



- Biology
- R&D
- Drug Discovery
- Bioinformatics
- **DMPK**
- ADME
- Toxicology
- Structural Biology
- Pre-Clinical

- Head of Lab
- Bioinformatics
- Clinical Data
- R&D IT
- Data Sciences
- Translational Medicine
- Digital Transformation
- **Omics**
- AI/ML
- Biostatistics
- Analytics
- Genome Informatics
- Security & Privacy
- Data Management

Meet Investors

- Venture Capital
- Private Equity
- Large Pharma/Biotech
- Corporate Venture Capital
- Institutional
- High Net Worth
- ✓ Family Office/Private Wealth
- Government Organisation/
- Sovereign Wealth Fund
- Angel



Biology



BioInformatics





Facilitator Faculty

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING WEST COAST USA 2024

Tuesday, 21st May 2024 🙎 Hard Rock Hotel San Diego



Adam Mullick Vice President, Cardiovascular Drug Discovery Ionis Pharma



Anastasia Velentza Senior Director, Head of Discovery Technology Plexium



Angela Huang Founder and President Tempo Bioscience



Amish Patel Senior Vice President **Technical Operations Calidi Biotherapeutics**



Bishnu Navak Senior Director/Site Head **Neologics Bio**



Dimitra Chalkia Vice President. Computational Biology **Athos Therapeutics**



Geza Ambrus-Aikelin Executive Director. Biology **Odyssey Therapeutics**



Igor Nasonkin Co-founder & CEO **Phythera Therapeutics**



John Leonard Chief Executive Officer Aeona **Pharmaceuticals**



Sanjeev Thohan Scientific Advisory Board Member Cogentis Therapeutics/ Phoenix Molecular **Designs**



Stephanie Truhlar Associate Vice President Eli Lilly

How Has Our **STRATEGY MEETINGS**

Benefit The Life Science Industry

BOOK NOW!

The meeting was excellent. Discussions were great and trying to get everyone around the table to participate made for great idea sharing."

Joseph Mancini — Head of Pharmacology, AdMare Bioinnovations

It was a pleasure for me to participate. I love this series. Please keep it up!"

Zhihua Sui — CSO, Head of Research & Preclinical Development, **Proteovant Therapeutics**







💟 @proventaintl



2024 Sponsors

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS STRATEGY MEETING WEST COAST USA 2024 Tuesday, 21st May 2024 & Hard Rock Hotel San Diego

THOUGHT LEADER



Hammerspace is the data orchestration system that unlocks innovation and opportunity within unstructured data. It orchestrates the data to build new products, uncover new insights, and accelerate time to revenue across industries like AI, scientific discovery, machine learning, extended reality, autonomy, corporate video and more. Hammerspace delivers the world's first and only solution to connect global users with their data and applications on any vendor's data center storage or public cloud services, including AWS, Google Cloud, Microsoft Azure and Seagate Lyve Cloud.

PARTNERING SPONSORS









BOOK NOW!


Global Sponsorship Opportunities

Proventa's end-to-end consulting division gather real-time business intelligence on the industry's needs, challenges, budgets and investment areas. We combine this information with your specific needs to enhance your business development strategy. With the wealth of intel we provide, Proventa guarantees tangible results for your business within twelve months of the event.

For Sponsorship Opportunites please contact:

SPONSORSHIP TEAM: info@proventainternational.com | +44 (0)20 3314 0100














Solution Agenda at a Glance

DRUG DISCOVERY BIOLOGY

STRATEGY MEETING WEST COAST USA 2024

TARGET IDENTIFICATION 8 HIT VALIDATION DIAGONO-0830 BERAFAST & REGISTRATION OPENING REFORTE PRESENTATION OPENING REFORTER PRESENTATION OPENING REFORTER PRESENTATION OPENING REFORTE		TRACK 1	TRACK 2	TRACK 3	TRACK 4	TRACK 5	New TRACK 6	
08:30 - 08:00 Continue are year or personal respective in the enhanced booking drugs for Cancer Personal drugs for Can					IN SILICO BIOLOGY / AI & ML		INVESTMENT &	
10-30-09-00 The enhanced botanical drugs for Cancer Therapeutics PRESENTER joy No. No., Co., Proc. of each Co., Co., Proc. o	08:00 - 08:30	BREAKFAST & REGISTRATION						
Part	08:30 - 09:00	The enhanced botanical drugs for Cancer Therapeutics						
OB-00-10:00 PARATIV Belling and the Wallington and HI Wallington (Top LTD) Belling and Top Line (Large LTD) Belling and Top LTD) Belling								
10:25 - 10-45 10	PHARMA/	Identification and Hit Validation in Drug Discovery Bishnu Nayak, Senior Director/	PBPK absorption modeling and its challenges (Topic TBC) Sanjeev Thohan, Scientific Advisory Board Member, Cogentis Therapeutics/Phoenix	Projection And Prediction To Aid	generative AI to transform drug	in instituting a data-driven drug	techniques in adapting go-to- market approach John Leonard, Chief Executive Officer, Aeona	
10:45 - 11:05 10:45	10:00 - 10:05	REFRESHMENT BREAK						
Problem ways to access greater target space and sepand the drugable geneme to a larger therapeutic area to discover new drugs (Topic TBC) SOLUTION IN:10 - 12:10 SOLUTION SPONSOR SPO	10:05 - 10:25	NETWORKING / 1-1 MEETINGS						
Problem ways to access greater targets, agree and separated the druggable genome to a larger therapeutic area discover new drugs (Topic TBC) A partial formation of Discovery and development of Solution from various platforms and paper and development of Solution from various platforms and paper and development of Solution from various platforms and paper and development of Solution from various platforms and paper and development of Solution from various platforms and paper and development of Solution from various platforms and paper and development of Solution from various platforms and paper and development of Solution from various platforms and development of Solution from various platforms and paper and development of Solution from various platforms and developmen								
models in pre-clinic technique green to a larger threapeutic area to discover new drugs (Topic TEC) Anastasia Velenta, Senior Vice Pharmacology i Resultan SPONSOR SPONSOR	10:45 - 11:05							
SPONSOR SPON		space and expand the druggable genome to a larger therapeutic area to discover new drugs (Topic TBC) Anastasia Velentza, Senior Director, Head of Discovery	In Silico, In Vivo And In Vitro Pharmacology To Enhance ADMET	models in pre-clinical testing and combining current in vitro technique	technologies/strategies and infrastructure tools to support	data integration with AI in drug	Understanding the need to source solutions from various platforms and approaches to generate ideas and inject innovations in drug discovery	
12:15 - 13:15 PHARMA/ BIOTECH Adam Mullick, Vice President, Cardiovascular Drug Discovery, Ionis Pharma Adam Mullick, Vice President, Cardiovascular Drug Discovery, Ionis Pharma METWORKING LUNCH NETWORKING / 1-1 MEETINGS AFTERNOON REFRESHMENT BREAK Advances in computation and mall models and machine learning techniques for amore precise prediction of ADME properties and process Dimitro Alexandro President, Tempo Bioscience NETWORKING / 1-1 MEETINGS AFTERNOON REFRESHMENT BREAK PANEL DISCUSSION: Discussion in making it happen to democratization and the factors to consider in making it happen to consider in mak		Technology, Plexium	SPONSOR	SPONSOR	SPONSOR	SPONSOR	SPONSOR	
14:00 - 14:20 14:40 - 15:10 Target validation and small molecule hit identification in the era of modern drug discovery PHARMA/ BIOTECH Target validation and small molecule hit identification in the era of modern drug discovery The rapeutics Advances in computational models and machine learning techniques for a more precise prediction of ADME problems of heterogenous diseased population Advances in computational models and machine learning techniques for a more precise prediction of ADME problems of heterogenous diseased problems of heterogenous diseased population Advances in computational models and machine learning techniques for a more precise prediction of ADME problems of heterogenous diseased problems of heterogenous diseased population AFTERNOON REFRESHMENT BREAK PANEL DISCUSSION: PARAMA/ BIOTECH PARAMA/ BIO	PHARMA/	Appropriate Modalities And Hit ID Strategies For First In Class Targets Adam Mullick, Vice President, Cardiovascular Drug Discovery,	and other microphysiological systems for high-throughput toxicity screening, ADME studies, and prediction of drug	improving nonclinical studies Angela Huang, Founder and	tools to expedite and increase efficiency in drug discovery process Stephanie Truhlar, Associate	democratization and the factors to	further drug discovery and development operations Amish Patel, Senior Vice President Technical Operations,	
14:40 - 15:10 Target validation and small molecule hit identification in the era of modern drug discovery PHARMA/ BIOTECH 16:10 - 16:30 Target validation and small molecule hit identification in the era of modern drug discovery Director, Biology, Odyssey Therapeutics Advances in computational models and machine learning techniques for a more precise prediction of ADME problem of heterogenous diseased population Advances in computational models and machine learning techniques for a more precise prediction of ADME problem of heterogenous diseased population Advances in computational models and machine learning techniques for a more precise prediction of ADME problem of heterogenous diseased population Advances in computational models and machine learning techniques to address the problem of heterogenous diseased population Biotech Advances in computational models and machine learning techniques for a more precise prediction of ADME problem of heterogenous diseased population For in-silic drug discovery process population in the era of modern drug discovery and its contribution in discovery and its co	13:15 - 14:00	NETWORKING LUNCH						
15:10 - 16:10 PHARMA/ BIOTECH Target validation and small molecule hit identification in the era of modern drug discovery Director, Biology, Odyssey Therapeutics Advances in computational models and machine learning techniques for a more precise prediction of ADME properties and process AFTERNOON KEYNOTE PRESENTATION Navigating the latest machine learning tools for in-silico drug discovery and its contribution in accelerating drug discovery process Dimetrac Chalkia, Vice President, Computational Biology, Athos Therapeutics AFTERNOON REFRESHMENT BREAK PANEL DISCUSSION: Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-market vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt	14:00 - 14:20	NETWORKING / 1-1 MEETINGS						
Target validation and small molecule hit identification in the era of modern drug discovery more precise prediction of ADME properties and process Signature Target validation and small molecule hit identification in the era of modern drug discovery more precise prediction of ADME properties and process Signature Target validation and small molecule hit identification in the era of modern drug discovery more precise prediction of ADME properties and process Signature Target validation and small molecule hit identification in the era of modern drug discovery more precise prediction of ADME properties and process Signature Target validation and small molecule hit identification in the era of modern drug discovery and its contribution in accelerating drug discovery and it	14:20 - 14:40	NETWORKING / 1-1 MEETINGS						
identification in the era of modern drug discovery PHARMA/BIOTECH identification in the era of modern drug discovery Geza Ambrus-Aikelin, Executive Director, Biology, Odyssey Therapeutics AFTERNOON REFRESHMENT BREAK PANEL DISCUSSION: PHARMA/BIOTECH Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt	14:40 - 15:10	AFTERNOON KEYNOTE PRESENTATION						
PANEL DISCUSSION: PHARMA/ BIOTECH PANEL DISCUSSION: PHARMA/ BIOTECH PANEL DISCUSSION: Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-market vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt	PHARMA/	identification in the era of modern drug discovery Geza Ambrus-Aikelin, Executive Director, Biology, Odyssey	and machine learning techniques for a more precise prediction of ADME	chip technology in combination with other techniques to address the problem of heterogenous diseased	learning tools for in-silico drug discovery and its contribution in accelerating drug discovery process Dimitra Chalkia, Vice President, Computational Biology, Athos	bioinformatics applications in novel	to initiate financial strategies using	
PHARMA/ BIOTECH Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-market vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt	16:10 - 16:30	AFTERNOON REFRESHMENT BREAK						
17:00 - 18:00 DRINKS & CANAPES RECEPTION	PHARMA/							
	17:00 - 18:00	DRINKS & CANAPES RECEPTION						





Find your new partner, explore our digital storefronts

www.pharmafeatures.com

Contact us to discuss how we can help generate growth for your business

Dex Marco Guibelondo

Marketing Content Writer, Proventa International Editor-in-Chief, PharmaFEATURES

dex@proventainternational.com



OUR FACE TO FACE MEETING IN MAY 2024



Hyatt Regency Princeton

STRATEGY

Hard Rock Hotel

San Diego

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS STRATEGY MEETING EAST COAST USA 2024

& BIOINFORMATICS

MEDICINAL CHEMISTRY

CLINICAL OPERATIONS & CLINICAL TRIAL SUPPLY CHAIN STRATEGY MEETING EAST COAST USA 2024

MEDICINAL DRUG DISCOVERY BIOLOGY CHEMISTRY STRATEGY MEETING WEST COAST USA 2024

CLINICAL OPERATIONS & CLINICAL TRIAL SUPPLY CHAIN **Hotel & Venue**



SAN DIEGO

Hard Rock Hotel San Diego

Hotel, we immerse you in our musical amenities, world-class service, and intoxicating location in downtown San Diego. Tour the Gaslamp Quarter on an Electra bike and walk a block to Petco Park.

BOOK NOW!

We only have limited rooms available!

Hotel Details >

Map & Directions >









Visit us on our website to know more about our meetings

www.proventainternational.com